Company & Sponsor Intelligence
Bial - Portela C S.A.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting0
Completed1
Countries1
Therapeutic footprint
epilepsy
Indexed studies
NCT00988156Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
epilepsy · AustriaPHASE3
epilepsy · AustriaPHASE3
NCT03093389Tolerability and Steady-state Pharmacokinetics of BIA 6-512
parkinsons · PortugalPHASE1
parkinsons · PortugalPHASE1
NCT02281526An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
epilepsy · South AfricaPHASE1
epilepsy · South AfricaPHASE1
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →